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1. Introduction 
Over 150 years ago, Cohnheim and Durante formalized the concept that cancers might arise 
from a small subset of cells with stem cell properties 1-3, and in 1961, Till and McCulloch 
demonstrated for the first time that the existence of hematopoietic stem cells (HSC) in the 
bone marrow, which was postulated that stem-like cells might be the origin of cancer 4. 
However, only recently did an increased interest in cancer stem cells (CSC) occur, thus 
spurring great advances in cancer stem cell biology. The CSC model was first developed in 
1994 when malignant initiating cells were discerned in human acute myeloid leukemia 
(AML) 5. Afterwards, similar CSC model was extended to some solid tumors that originated 
in the breast, brain, lung, prostate, colon, head and neck, and pancreas 6-12. Most 
importantly, the development of CSC hypothesis has fundamental implications in terms of 
understanding the biology of muti-step tumorigenesis, the prevention of cancer, and the 
creation of novel effective strategies for cancer therapy. 
1.1 The definition of cancer stem cells 
It is well documented that tumors contain cancer cells with heterogeneous phenotypes 
reflecting aspects of their apparent state of differentiation. In a tumor, the mutable 
expression of normal differentiation markers by cancer cells implies that some of the 
heterogeneity arises as a result of this altered manifestation. Also, cancer is known to be the 
product of the accumulation of multiple genetic mutations and epigenetic alterations in a 
single target cell, the occurrences of which can sometimes take place over many decades. 
Furthermore, chemotherapy and radiation therapy for cancers have limited effectiveness in 
long-term scenarios, and the possible recurrence of tumors after years of disease-free 
survival exists in great majority of cancers. All these observations provide persuasive 
evidence that tumors are not mere monoclonal expansions of cells but might contain a 
subset of long-lived tumor-initiating cells with the ability to self-renew indefinitely and to 
regenerate the phenotypic diversity of original tumor 13. This subpopulation is now widely 
termed as cancer stem cells (CSCs), also named tumor-initiating cells (T-IC). The exist of 
CSCs within a tumor was also supported by in vitro ‘‘clonogenic assays’’ that showed 
subpopulations of tumor cells (with increased proliferative capacity) using cells isolated 
from tumor specimens, as well as by in vivo self-renewal assays that indicated only a small 
specific subset of cancer cell population had tumorigenic potential when injected into 
immunodeficient mice 13, 14.  
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The definition of CSCs is defined by two main properties: 1) self-renewal that drives 
tumorigenesis: the ability to form new CSCs with potential for proliferation, expansion, and 
differentiation; 2) multipotent differentiation, which contributes to the cellular heterogeneity 
of a tumor: the ability to give rise to a heterogeneous progeny of tumor cells, which 
diversify in a hierarchical manner. 
When distinguished from the majority of differentiated cancer cells, CSCs are resistant to 
many current cancer treatments, including chemo- and radiation therapy 15-20. This suggests 
that lots of cancer treatments, while targeting the majority of tumor cells, may fail in the end 
due to not eliminating CSCs, which survive by developing new tumors. However, this 
would open avenues for developing novel effective drugs targeting CSCs. Although CSCs 
share several properties (i.e. the ability to self-renew and to differentiate, increased 
membrane transporter activity, the capacity for migration and metastasis, the same intrinsic 
signaling pathways (Notch, Wnt, Hedgehog etc) for regulation of self-renewal etc) with the 
normal stem cells 21, they are found to have some particular characteristics. For instance, the 
proliferation and self-renewal of CSCs are uncontrolled and unlimited (sometimes referred 
to as “immortality”), and the CSCs always differentiate into abnormal cancer cells, thus they 
cannot give rise to mature somatic cells 22. This reveals that therapies targeted at extrinsic 
signals generated in the microenvironment (such as CXCR1, endothelial cell-initiated 
signaling, IL-6 and CXCL7) 23-25 or microRNAs (see Part 3 of this chapter) 26-29, which are 
found to specifically regulate self-renewal and/or differentiation of CSCs, might achieve 
clinical success with little adverse effects in cancer treatment.  
1.2 Leukemia stem cells: The first cancer stem cells identified 
In the early 1990s, Dick and his colleagues started a series of groundbreaking investigations to 
understand whether the functional hierarchy observed in normal hematopoiesis was 
conserved in leukemia 5, 30. They used magnetic separation techniques and purified cells from 
AML patients into several groups according to different surface markers. These groups of cells 
were then implanted into immunocompromised mice and assessed for the ability to produce 
leukemic colony forming units. Interestingly, only the CD34+ CD38- subpopulation of 
leukemic cells had the ability to generate substantially more leukemic colonies in vivo. As well, 
they found that CD34+ CD38- leukemic stem cells retained differentiative capacity, giving rise 
to CD38+ and Lin+ populations. These observations provided the first compelling evidence 
that in a human cancer, there was a small population of self-renewing, tumorigenic stem cells.  
1.3 Solid tumor stem cells 
Subsequent experiments extended the leukemic stem cell model to human solid tumors. In 
the year 2003, Al-Hajj et al reported the identification of CSCs in human breast cancer, the 
first solid tumor that the existence of a functional hierarchy stem cell system had been 
demonstrated 7. In their experiments, human breast cancer specimens obtained from 
primary or metastatic sites in nine different patients all engrafted in the NOD/SCID (non-
obese diabetic/severe combined immune deficiency) mice. They observed that in most 
human breast cancers, only a minority subset of the tumor clones (defined as CD44+, 
CD24−/low and representing 11%–35% of total cancer cells) is endowed with the capacity to 
maintain tumor growth when xenografted in NOD/SCID mice. Importantly, tumors grown 
from the CD44+, CD24−/low cells were shown to contain mixed populations of epithelial 
tumor cells, recreating the phenotypic heterogeneity of the parent tumors. The small 
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subpopulation of cells was further enriched by sorting for those that expressed epithelial 
surface antigen (ESA). More interestingly, 200 of the enriched ESA+CD44+CD24−/low cells 
were able to form a tumor following injection into a NOD/SCID mouse, while 20,000 of the 
CD44+CD24+ cells failed to do so 7. In summery, these results opened a new chapter in the 
understanding of the biology of CSCs in human solid tumors.  
Soon after, Michael F. Clarke’s group published similar data about CSCs in brain tumors 8, 
31. They carried out studies to enrich tumorigenic cells in glioblastoma multiforme and 
medulloblastoma by sorting for those that express positive / high levels of CD133, a neural 
cell surface stem cell antigen. CD133high cells formed numerous colonies in suspension 
culture, and injection of as few as 1000 of these cells into an immunocompromised mouse 
successfully form a tumor. Conversely, CD133low cells showed very limited proliferative 
potential in vitro, and as many as 10,000 of these cells failed to seed tumors in host mice 8. 
Furthermore, tumors developing from orthotopic, intracerebral injection of the minority of 
CD133+/high cells (about 5% - 30% of total tumor cells) reproduced the phenotypic diversity 
and differentiation pattern of the parent tumors 31.  
As mentioned earlier, comparable results have been obtained in other solid tumors, like 
lung, prostate, colon, head and neck, as well as pancreatic 6, 9-12. 
2. Isolation and identification of breast cancer stem cells 
In most tumor tissues, including breast cancer, CSCs are rare. As we know, breast cancer is a 
histologically and molecularly heterogeneous disease, with six different subtypes, including 
luminal A, luminal B, normal breast-like, basal-like, claudinlow and HER2 overexpressing, 
which are characterized by distinct histology, gene expression patterns, and genetic 
alterations 32-35. The molecular heterogeneity between breast cancers has been revealed to 
issue from different targets of transformation. Recent studies found that basal-like breast 
cancers with BRCA1 mutations were more likely to arise from luminal progenitors rather 
than the basal stem cells 36, 37. However, further studies that focus on breast CSCs and 
mammary stem/progenitor cells as well as their potential relationship are needed for 
determining the exact origin of luminal versus basal-like cancers, with the aim of 
developing targeted therapies for different subtypes of breast cancers. Moreover, CSCs was 
found to be the main culprit for the failure of chemo- and radiation therapy, as well as the 
seeds for the distant metastasis and relapse in breast cancers 20, 32, 38-40. Taken together, in 
order to better understand the properties and biology of breast CSCs and eventually cure 
breast carcinoma, it is absolutely necessary and important to identify and separate breast 
CSCs prospectively.  
2.1 Isolation of breast CSCs with cell-surface marker profiles  
Since Dick, et al isolated a specific subpopulation of leukemia cells (that expressed surface 
markers similar to normal hematopoietic stem cells) which was consistently enriched for 
clonogenic activity in NOD/SCID immunocompromised mice from acute myeloid 
leukemias in the 1990s 5, 30, scientists attempted to see if they could enrich CSCs in human 
solid tumors by sorting for different cellular markers. CD24, a ligand for P-selectin in both 
mouse and human cells, was identified as a significant marker for human breast carcinoma 
invasion and metastasis 41, 42, and another adhesion molecular CD44 was found to correlate 
with cellular differentiation and lymph node metastasis in human breast cancers 43, 44, 
whereas B3.8 was described as a breast / ovarian cancer-specific marker 45. Based on these 
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observations, in 2003, Al-Hajj et al tried to determine whether these surface markers could 
distinguish tumorigenic from nontumorigenic cells, and flow cytometry was used to isolate 
cells that were positive or negative for each marker. They demonstrated that a small 
population of tumorigenic cells, isolated from human breast tumors and characterized by 
the expression of the cell surface markers CD44+CD24−/lowLineage−, was capable of 
regenerating the phenotypic heterogeneity of the original tumor when injected 
subcutaneously into NOD/SCID mice 7. They showed that as few as 100 cells with 
CD44+CD24−/low phenotype could form tumors in immunodeficient mice, while 
thousands of cells with fungible phenotypes failed to do so. Since then, CD44 and CD24 are 
widely accepted as surface markers for breast CSCs, and lots of studies have focused on 
roles of CD44+CD24− tumor cells in breast cancers. For example, Abraham et al. conducted 
immunohistochemical studies of CD44+CD24− tumor cells in human breast tumors and 
showed that breast tumors containing a high proportion of CD44+CD24− cells were 
associated with distant metastases 46.  
Nevertheless, besides CD24 and CD44, there are other surface marker candidates for the 
enrichment of breast CSCs. Ginestier et al. reported that they separated breast cancer 
stem/progenitor cells by sorting for Aldehyde dehydrogenase 1 (ALDH1), a detoxifying 
enzyme responsible for the oxidation of intracellular aldehydes 47, 48, and they found that 
fewer ALDH1-positive than CD44+CD24− tumor cells are required to produce tumors in 
immunodeficient mice 49. Additionally, recent studies revealed that ALDH1-positive seemed 
to be a more significantly predictive marker than CD44+CD24− for the identification of 
breast CSCs, in terms of resistance to chemotherapy and more metastatic 39, 50. Moreover, it 
has been reported that the surface marker CD133 could isolate a group of breast CSCs that 
doesn’t overlap with CD44+CD24− cells 51; and another recent study demonstrated that in a 
basal breast cancer cell line MDA-MB-231 (known as triple-negative), PROCR and ESA, 
instead of CD44+CD24−/low and ALDH, could be used to highly enrich breast cancer 
stem/progenitor cell populations which exhibited the ability to self renew and divide 
asymmetrically 52. 
2.2 Separation of breast CSCs by selecting for side-population (SP) cells 
Advances in the separation of breast CSCs was accelerated by the identification of side 
population (SP) cells, due to lack of dye retention and chemotherapy efflux 53. The method is 
based on cells incubated with Hoechst dye 33342 or rhodamine, after which the cells are 
analyzed by flow cytometry for dye exclusion and size, and SP cells would not retain dye. 
Isolation of SP cells facilitates purification of adult tissue stem cells comprising human and 
murine hematopoietic stem cells and a population of putative mammary epithelial stem 
cells 54-57. Moreover, because some evidence revealed that breast CSCs and mammary 
epithelial stem cells represent biologically related entities 58, scientists thought to apply this 
technique to isolate breast CSCs. In 2005, Patrawala et al successfully isolated SP cells from 
an ER-positive human breast cancer cell line MCF-7, and they demonstrated that these small 
subset (0.2%) SP cells preferentially express stemness-associated genes (such as Notch1 and 
β-catenin) and verapamil-sensitive ATP-binding cassette (ABC) transporter ABCG2 mRNA 
59. More interestingly, MCF-7 SP cells were highly tumorigenic, whereas MCF-7 non-SP cells 
could not give rise to tumors in mice at al59. Researchers then took advantage of similar 
method to separate SP cells with stem cell properties from an ER-negative human breast 
cancer cell line Cal-51 and an triple-negative human breast cancer cell line MDA-MB-231, 
respectively, and they both found the SP cells expressed high levels of ABCG2 60, 61. Previous 
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studies showed that SP cells takes advantage of their ability to pump out the fluorescent dye 
Hoechst 33342 (H33342) through the ABCG2 (also known as breast cancer resistance 
protein-1), which was regarded as a major mediator of dye efflux in various stem cells 54, 62. 
As the ability to efflux substrates is particularly important for the protection of CSCs, and 
CSCs survive after chemotherapy partially by effluxing cytotoxic drugs, ABCG2 seems to 
protect stem cells from toxins. This is evident in ABCG2 knockout mice that are more 
sensitive to compounds such as vinblastine, ivermectin, topotecan, and mitoxantrone 63-65. 
Taken together, SP cells have the capacity to efflux toxic substances out of breast cancer stem 
like cells via an ABCG2-mediated cytoprotective mechanism and seem to contribute to 
chemotherapy-resistance. In addition, it is important to consider that identification of cancer 
stem like cells by selecting for SP cells is not limited to breast carcinomas. Similar 
observations have been made in other solid tumors (such as glioma, ovarian and pancreatic 
cancers) where the isolated SP cells proliferated infinitely and could regenerate heterologous 
NSP cells in culture 59, 66-68.  
2.3 Propagation of breast CSCs by isolating ‘‘mammospheres’’ from suspension 
cultures 
Colonial growth in nonadherent culture was used to test for self-renewal capacity in cultures 
of neural cell in 1996, and in the experiment, suspension culture led to formation of 
“neurospheres”, which consisted of 4% - 20% normal neural stem cells 69. Based on this 
approach, Galli et al. succeeded in the characterization and isolation from human glioblastoma 
multiform of “cancer neurospheres”, which were highly enriched in long-term self-renewing, 
multi-lineage-differentiating, and tumor-initiating cells 70. According to these successful 
procedures, researchers tried to extend this technology to the identification and propagation 
of mammary epithelial stem cells and breast CSCs. In 2003, Dontu et al. demonstrated that 
nonadherent mammospheres are enriched in human mammary epithelial progenitor/stem 
cells and able to differentiate along all three mammary epithelial lineages and to clonally 
generate complex functional structures in reconstituted 3D culture systems 55. More 
encouragingly, two years later (2005), Ponti and colleagues reported the isolation and in 
vitro propagation of spherical clusters of self-replicating cells (‘‘mammospheres’’) with 
stem/progenitor cell properties in suspension cultures from three breast cancer lesions and 
from an established breast carcinoma cell line MCF-7 71. They found that the isolated cells 
which overexpressed neoangiogenic and cytoprotec-tive factors showed CD44+CD24- and 
Cx43-, and expressed the stem cell marker OCT-4, and could form tumors in vivo when as 
few as 103 cells were implanted. This was the first time showing that breast tumorigenic cells 
with stem/progenitor cell properties can be propagated in vitro as nonadherent 
mammospheres, and accordingly, this experimental system was then frequently used by 
researchers for isolating and studying the breast tumor–initiating cells (BT-IC) 72-74.  
2.4 Novel strategies for enrichment of breast CSCs 
As we mentioned in the first part of this chapter, the cancer stem cell hypothesis suggests 
that many cancers are maintained in a hierarchical organization of rare, slowly dividing 
CSCs (or T-IC), rapidly dividing amplifying cells (early precursor cells, EPC) and post-
mitotic differentiated tumor cells 22. Thus, the complex scheme which operates in most 
tumor tissues seems to be that the slowly dividing CSCs give birth to EPC, which then 
undertake a program of exponential growth for a limited period of time before the 
descendant cells differentiate and become post-mitotic (Figure 1). Although the above three 
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classical methods are widely used for the isolation and identification of breast CSCs, these 
methods purify both T-IC and some EPC 7 59, 71. To study the breast CSCs more accurately, 
our group was trying to search for new strategies to enrich more purified breast CSCs. We 
found that breast carcinomas from chemo-treated patients were highly enriched for cells 
with the properties of BT-IC. We then sequentially passaged tumor cells in epirubicin-
treated NOD/SCID mice to get a highly malignant breast cancer cell line (SK-3rd) using the 
chemo-therapeutic resistance of BT-IC. Our SK-3rd cell line showed all the tentatively 
defined properties of BT-IC, including enhanced mammosphere formation, multipotent 
differentiation, chemo-therapy resistance, as well as BT- IC 
phenotype(OCT4+CD44+CD24−lin−)76 (Figure 2). We assess that about 16% of SK-3rd cells 
were T-IC, while the rest cells (also CD44+CD24−) were mostly EPC, and mammospheric 
SK-3rd cells were ～100-fold more tumorigenic in vivo than the parent cell line, metastasize, 
and can be serial xenotransplanted26. Additionally, SK-3rd cells was capable of providing 
unlimited numbers of cells for BT-IC studies. This method of in vivo chemotherapy may 
provide researchers a novel approach of selecting CSCs from other breast cancer lines or 
possibly for other cancers. 
 
 
Fig. 1. A Model of the Cellular Hierarchies that May Exist in Human Cancers. 
Besides our strategy, there might be other new approaches for generating breast CSCs. The 
epithelial-mesenchymal transition (EMT) is a key developmental program that is often 
activated during cancer progression, invasion and metastasis. Associations between the 
breast CSCs and EMT hypothesis of cancer were established recently as similarities in these 
two ideas were noted (will be discussed in Part 4 of this chapter). Several very recent studies 
have found that the EMT could generate mammary epithelial stem cells and breast CSCs 77-
79. This may provide potential novel methods to generate and enrich relatively unlimited 
numbers of breast CSCs, whose biology may then be studied with far greater facility.  
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The complex scheme which operates in most tumor tissues seems to be that the slowly 
dividing CSCs give birth to the rapidly dividing amplifying cells (early precursor cells, EPC), 
which then differentiate into post-mitotic tumor cells after a small number of cell divisions.  
 
 
Fig. 2. Breast Cancer Cells under Pressure of Chemotherapy Are Enriched for BT-IC. 
(A and B) 1°breast cancers from patients who received neoadjuvant chemotherapy are 
substantially enriched for self-renewing cells with the expected properties of BT-IC. 
Representative images show increased numbers of mammospheres after 15 days of culture 
(A) and a higher percentage of CD44+CD24- cells in freshly isolated tumors (B) from a 
patient who received chemotherapy. (C) Similarly, passaging the human breast cancer line 
SKBR3 in epirubicin-treated NOD/SCID mice enriches for cells with BT-IC properties. 
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Shown are numbers of 1°, 2°and 3°mammospheres on day 15 from 1000 cells. (D) 
Mammospheres generated from single-cell cultures of SK-3rd and SKBR3, imaged on 
indicated day of suspension culture. (E) The majority of freshly isolated SK-3rd cells are 
CD44+CD24-, while cells with this phenotype are rare in SKBR3. (F) SK-3rd and SKBR3 cells 
cultured as spheres are CD44+CD24-. When they differentiate in adherent cultures, they 
gradually assume the parental SBKR3 phenotype, but somewhat more rapidly for SKBR3 
mammospheres. (G) When SK-3rd spheres are removed from growth factors, and plated on 
collagen for 8 hr (top), they do not express luminal (Muc1 and CK-18) or myoepithelial (CK-
14 and a-SMA) differentiation markers, while after further differentiation (bottom), they 
develop into elongated cells with subpopulations staining for either differentiated subtype. 
(H) Freshly isolated SK-3rd cells are enriched for Hoechstlow SP cells compared with SKBR3 
cells26. Adapted from Yu F, et al.Cell, 2007: 131:1109-23. 
3. The dysregulation of MicroRNAs in breast cancer stem cells 
MicroRNAs (miRNAs) are endogenously synthesized small non-coding RNAs, 19-25 
nucleotides in length that negatively regulate gene expression by repressing translation of 
target mRNAs or targeting them for degradation80. The active miRNA is produced by the 
RNase III enzyme Dicer in the cytosol from a precursor-miRNA (pre-miRNA) by removing 
the loop of the pre-miRNA stem-loop. The Dicer-processed miRNA is then taken up by the 
RNA-induced silencing complex (RISC), which becomes activated when one strand (the 
antisense or guide strand) is incorporated into the complex and the other strand separates 
and is discarded. The activated RISC complex can then seek out target mRNAs, which have 
partially complementary sequences to the guide strand (often in their 3’-UTR), and suppress 
their translation into protein81.  
MiRNA expression is altered in cancer cells and can be used to predict tumor type and 
prognosis. Cancer-associated miRNAs are frequently deleted, mutated or associated with 
satellite DNA expansions in cancers, suggesting that these molecules serve as important 
regulators of tumor development82. Emerging evidence has made it clear that miRNAs also 
function as important regulators of stemness, collaborating in the maintenance of the 
pluripotency, control of self-renewal, and differentiation of both normal stem cells and 
CSCs83. Except for certain miRNAs have high level transcripts, the global downregulation of 
miRNAs are present in CSCs when compared to their differentiated counterparts82. 
Dysregulation of miRNAs may result in excessive self-renewal and survival of CSCs which 
is a likely cause for the chemo-resistance and relapse in tumor patients.  
MiRNAs can serve as either tumor suppressors or oncogenes depend on their expression 
levels in CSCs. Tumor suppressor miRNAs are supposed to inhibit tumor progression while 
their expression is downregulated. Oncogenic miRNAs are often called oncomiRs and are 
upregulated in the cancer cells84. 
3.1 Tumor suppressors 
Let-7 is the first human miRNA to be discovered and its expression has been observed to be 
reduced in a number of tumor cell lines including lung and breast cancer85. Recent research 
indicated let-7 acted as tumor repressor playing an important role in the self-renewal 
potential of cancer stem cells. Yu and colleagues demonstrated that let-7 family was not 
expressed by breast CSCs generated from cell lines or 1°patient tumors and increased with 
differentiation. By expressing of let-7 in breast CSCs or antagonizing let-7 in more 
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differentiated cells, it was found that let-7 regulated the key features of breast CSCs—self 
renewal in vitro, multipotent differentiation, and the ability to form tumors. Because the two 
targets of let-7 RAS and HMGA2 were responsible for the self renewal and multipotent 
differentiation, respectively, aberrant expression of let-7 in breast CSCs helps to maintain 
their stemness26. 
Recently, Yu et al. found that similar to let-7, the expression of miR-30 was reduced in breast 
cancer stem-like cells (BT-ICs), and its target genes, Ubc9, an E2-conjugating enzyme 
essential for sumoylation, and integrin ß3(ITGB3), were upregulated at protein levels. 
Overexpression of miR-30 in BT-ICs inhibited their self-renewal ability by repressing Ubc9 
and promoted apoptosis by inhibiting Ubc9 and ITGB3. Furthermore, ectopic expression of 
mir-30 or blocking the expression of Ubc9 in BT-ICs xenografts reduced their tumor-forming 
capacity and metastasis in NOD/SCID mice, while miR-30 inhibitor enhanced 
tumorigenesis and metastasis of SKBR3 breast cancer cells with low metastasis potential86. 
These results suggested that miR-30 could be one of the important miRNAs in regulating 
the stem-like features of breast cancer 
MiR-15/ miR-16 are also tumor suppressors. It was first identified in B cell chronic 
lymphocytic leukaemia (B-CLL) that miR-15/ miR-16 was lower in their expression level 
while their target protein the anti-apoptosis Bcl-2 was overexpressed87. The downregulation 
or deletion of miR-15/miR-16 was also found in other cancer types, such as prostate 
cancer88, pituitary adenomas89, non-small cell lung cancer (NSCLC)90, and ovarian cancer91. 
Expression of these miRNAs inhibited cell proliferation, promoted apoptosis, and 
suppressed tumorigenicity both in vitro and in vivo by targeting multiple oncogenes, 
including Bcl-2, MCL1, CCND1, Wnt3A and Bmi-1. There has been growing evidence 
illustrated that the pivotal signaling pathways of the “stem cell genes”: Notch, Hedgehog, 
Wnt, HMGA2, Bcl-2 and Bmi-1 were involved in the self-renewal of CSCs92. Since the 
oncogenic activation of Bmi-1, Bcl-2 and Wnt3A were frequently correlated with the 
downregulation of miR-15/miR-16, it was strongly suggested miR-15/miR-16 played a key 
role in the regulation of CSCs. 
MiR-34 has been implicated in cell cycle control related to p5393. In p53 deficicent human 
gastric cancer cells, restoration of functional miR-34 inhibited the formation of tumorsphere 
in vitro and tumor initiation in vivo94. In parallel, miR-34 was reported to be involved in 
pancreatic CSCs self-renewal95. The mechanism of miR-34 mediated suppression of self-
renewal of CSCs was potentially related to the direct modulation of downstream targets Bcl-
2 and Notch, suggesting that miR-34 might play an important role in gastric and pancreatic 
CSCs’ self-renewal and/or cell fate determination. However, reduced expression of miR-34a 
in prostate cancer stem cells facilitated tumor development and metastasis by directly 
regulating CD44. Accordingly, CD44 knockdown inhibited prostate cancer growth and 
metastasis96. These results provided a solid experimental basis for developing miR-34a as a 
promising therapeutic agent against prostate CSCs. 
MiR-128 is also a tumor suppressor involved in CSCs. Its expression was dramatically 
reduced in high grade gliomas, while application of miR-128 inhibited glioma proliferation 
and self-renewal by targeting Bmi-1 oncogene/stem cell renewal factor97. Same result was 
found in neural tumor medulloblastoma that miR-128a had growth suppressive activity in 
medulloblastoma and this activity was partially mediated by targeting Bmi-1 and thereby 
increasing the steady-state levels of superoxide and promoting cellular senescence. This data 
has implications for the modulation of redox states in CSCs, which are thought to be 
resistant to therapy due to their low ROS states98. 
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miR-200 is an evolutionary conserved family which were found to be strongly suppressed in 
CD44+/CD24− lineage human breast cancer cells27 and poorly differentiated pancreatic 
adenocarcinomas99. Recent research conducted in an inducible oncogenesis model showed 
that inhibition of miR-200b expression resulted in enrichment of the CSC population, and 
CSC or mammosphere growth was blocked by overexpression of miR-200b. Meanwhile one 
of its target Suz12 subunit of PRC2 was increased in CSC which in turn repress the 
transcription of E-cadherin. Thus, miR-200b acts as a tumor suppressor that blocks the 
formation and maintenance of mammospheres by targetting Suz12-E-cadherin pathway100. 
These results identified miR-200 microRNA family as a critical regulator for CSC growth 
and function. 
3.2 Oncogenes 
The miR-17-92 polycistron which is composed of 7 members is found to be overexpressed in 
multiple tumors, including lung101, lymphoma102, myeloid leukemias103, hepatocellular   
carcinomas104, medulloblastoma105 and colorectal106. It’s known to function as oncogenes to 
promotes cell proliferation and tumor progression. Introduction of miR-17-92 into 
hematopoietic stem cells was shown to significantly accelerated the formation of lymphoid 
malignancies partly by inhibiting apoptosis101. Also Wang et al found members of the miR-
17 family were notably more abundant in a mouse model of MLL leukemia stem cells 
compared with their normal counterpart granulocyte-macrophage progenitors and 
myeloblast precursors. Forced expression of miR-17-19b in leukemia cells, was consistent 
with a higher frequency of leukemia stem cell, reduced differentiation and increased 
proliferation. The oncogenic effects of miR17-92 on leukemia stem cell self-renewal in MLL-
associated leukemia in part due to modulating the expression of p21, a known regulator of 
normal stem cell function103. Taken together, these studies implicated the miR-17-92 cluster 
as a potential human oncogene that played a role in cancer stem cells. 
The miR-181 has an oncogenic role within cancers as well. MiR-181 family members were 
up-regulated in EpCAM(+)AFP(+) hepatocellular carcinoma(HCCs) and in EpCAM(+) HCC 
cells isolated from AFP(+) tumors which have the cancer stem/progenitor cell features. 
Downregulation of miR-181 reduced EpCAM(+) HCC cell quantity and tumorigenesis, 
whereas enforced expression of miR-181 in HCC cells resulted in an enrichment of 
EpCAM(+) HCC cells. The mechamism underlying the regulation of miR-181 on the 
stemness of EpCAM(+) HCC cells was partially by negatively regulating two hepatic 
transcriptional regulators of differentiation and an inhibitor of Wnt/_-catenin signaling 
(nemo-like kinase [NLK])107. Other evidence also showed miR-181 was elevated in breast 
cancer stem cells. Overexpression of miR-181a/b, or depletion of its target ataxia 
telangiectasia mutated(ATM), was sufficient to induce sphere formation in breast cancer 
cells and promote tumorgenesis108.  
3.3 EMT 
The epithelial-mesenchymal transition (EMT) is a vital developmental process that is often 
activated during cancer invasion and metastasis. During EMT, epithelial cells lose its 
epithelial characteristics including cell polarity and acquire mesenchymal phenotypes. On 
the molecular level, cells undergoing EMT down-regulated epithelial markers such as E-
cadherin and up-regulated mesenchymal markers such as N-cadherin, vimentin, and 
fibronectin109. Mani and colleagues were the first group to demonstrated that the 
immortalized human mammary epithelial cells (HMLEs) undergoing EMT displayed not 
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only mesenchymal traits, also cancer stem cell like properties as characterized by their 
CD44high/CD24low phenotype and increased ability to form mammospheres. On the other 
hand, HMLE mammospheres expressed markers similar to those of HMLEs that have 
undergone an EMT77. These findings illustrated EMT cells have cancer stem cell features 
and CSCs exhibit mesenchymal phenotype.  
MiR-200 is the most discussed family that involved in the regulation of EMT process. 
Several studies have demonstrated suppression of endogeneous miR-200 family members 
was sufficient to induce EMT, whereas their ectopic expression induces MET in normal and 
cancer cell lines through direct targeting of ZEB1/2110. While in CSCs with EMT phenotypes, 
miR-200 was also detected to be aberrant or absent in breast, pancreas and prostate. Wellner 
et al showed ZEB1 not only promoted tumor cell dissemination, but also was necessary for 
the maintaining a stem cell phenotype of pancreatic and colorectal cancer cells by inversely 
inhibiting the stemness-inhibiting miR-200 family members111. Hence, ZEB/miR-200 
feedback loop is a driving force for cancer progression towards metastasis by controlling the 
state of CSCs. MiR-200 and let-7 both were differentiation associated miRNAs, sometimes 
they work together regulating the EMT status of CSCs. It has been shown in prostate cancer 
cells the expression of miR-200 and/or let-7 was decreased in EMT phenotypic tumor cells 
which also expressed stem-like cell features as defined by increased expression of Sox2, 
Nanog, Oct4, Lin28B and/or Notch1. Restoration of miR-200 in prostate cancer cells 
inhibited the EMT process, as well as the clonogenic and sphere (prostasphere)-forming 
ability and tumorigenecity in mice which was consistent with the inhibition of Notch1 and 
Lin28B expression. Along with the decreased expression of Lin28, let-7 was increased which 
further repressed self-renewal capability112.  
As discussed above miRNAs are critically involved in the regulation of CSCs and EMT 
which were considered the “root causes” of chemo-resistant and tumor relapse. Therefore, 
targeting specific miRNAs could be a very promising therapeutic approach for the treatment 
optimization aiming at restoring the sensitivity of drug-resistant cells to chemotherapy. If it 
was possible to introduce miRNA mimics and/or antagonists into CSCs, it could in 
principle result in reversal of the some of the cells’ tumorigenic properties. However, from a 
clinical/translational research point of view, the critical hurdle to developing this type of 
approach for cancer therapy is to find an efficient way to selectively deliver miRNAs into 
CSCs or just cancer cells, but not normal tissues. So far the effective and safe therapeutics are 
still to be studied.  
4. References 
[1] J, C. Ueber entzundung und eiterung. Path Anat Physiol Klin Med 40, 1-79. (1867). 
[2] J, C. Congenitales, quergestreiftes Muskelsarkon der Nireren. Virchows Arch, 64-65. 
(1875). 
[3] F, D. Nesso fisio-pathologico tra la struttura dei nei materni e la genesi di alcuni tumori 
maligni. Arch Memor Observ Chir Pract 11, 217-226. (1874). 
[4] Till, J. E. & Mc, C. E. A direct measurement of the radiation sensitivity of normal mouse 
bone marrow cells. Radiat Res 14, 213-22 (1961). 
[5] Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation 
into SCID mice. Nature 367, 645-8 (1994). 
[6] Li, C. et al. Identification of pancreatic cancer stem cells. Cancer Res 67, 1030-7 (2007). 
www.intechopen.com
 
Breast Cancer – Focusing Tumor Microenvironment, Stem Cells and Metastasis 
 
284 
[7] Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. 
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S 
A 100, 3983-8 (2003). 
[8] Singh, S. K. et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 
63, 5821-8 (2003). 
[9] Kim, C. F. et al. Identification of bronchioalveolar stem cells in normal lung and lung 
cancer. Cell 121, 823-35 (2005). 
[10] Xin, L., Lawson, D. A. & Witte, O. N. The Sca-1 cell surface marker enriches for a 
prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. 
Proc Natl Acad Sci U S A 102, 6942-7 (2005). 
[11]  O'Brien, C. A., Pollett, A., Gallinger, S. & Dick, J. E. A human colon cancer cell capable 
of initiating tumour growth in immunodeficient mice. Nature 445, 106-10 (2007). 
[12] Prince, M. E. et al. Identification of a subpopulation of cells with cancer stem cell 
properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 
104, 973-8 (2007). 
[13] Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer 
stem cells. Nature 414, 105-11 (2001). 
[14] Clarke, M. F. A self-renewal assay for cancer stem cells. Cancer Chemother Pharmacol 
56 Suppl 1, 64-8 (2005). 
[15] Gupta, P. B. et al. Identification of selective inhibitors of cancer stem cells by high-
throughput screening. Cell 138, 645-59 (2009). 
[16] Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the 
DNA damage response. Nature 444, 756-60 (2006). 
[17] Dean, M., Fojo, T. & Bates, S. Tumour stem cells and drug resistance. Nat Rev Cancer 5, 
275-84 (2005). 
[18] Diehn, M. et al. Association of reactive oxygen species levels and radioresistance in 
cancer stem cells. Nature 458, 780-3 (2009). 
[19] Li, X. et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl 
Cancer Inst 100, 672-9 (2008). 
[20] Woodward, W. A. et al. WNT/beta-catenin mediates radiation resistance of mouse 
mammary progenitor cells. Proc Natl Acad Sci U S A 104, 618-23 (2007). 
[21] Wicha, M. S., Liu, S. & Dontu, G. Cancer stem cells: an old idea--a paradigm shift. 
Cancer Res 66, 1883-90; discussion 1895-6 (2006). 
[22] Dalerba, P., Cho, R. W. & Clarke, M. F. Cancer stem cells: models and concepts. Annu 
Rev Med 58, 267-84 (2007). 
[23] Ginestier, C. et al. CXCR1 blockade selectively targets human breast cancer stem cells in 
vitro and in xenografts. J Clin Invest 120, 485-97 (2010). 
[24] Krishnamurthy, S. et al. Endothelial cell-initiated signaling promotes the survival and 
self-renewal of cancer stem cells. Cancer Res 70, 9969-78 (2010). 
[25] Liu, S. et al. Breast cancer stem cells are regulated by mesenchymal stem cells through 
cytokine networks. Cancer Res 71, 614-24 (2011). 
[26] Yu, F. et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 
131, 1109-23 (2007). 
[27] Shimono, Y. et al. Downregulation of miRNA-200c links breast cancer stem cells with 
normal stem cells. Cell 138, 592-603 (2009). 
[28] Liu, C. et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis 
by directly repressing CD44. Nat Med 17, 211-5 (2011). 
[29] Yu, F. et al. MiR-30 reduction maintains self-renewal and inhibits apoptosis in breast 
tumor-initiating cells. Oncogene 29, 4194-204 (2010). 
www.intechopen.com
 
Breast Cancer Stem Cells 
 
285 
[30] Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that 
originates from a primitive hematopoietic cell. Nat Med 3, 730-7 (1997). 
[31] Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396-
401 (2004). 
[32] McDermott, S. P. & Wicha, M. S. Targeting breast cancer stem cells. Mol Oncol 4, 404-19 
(2010). 
[33] Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-52 
(2000). 
[34] Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor 
subclasses with clinical implications. Proc Natl Acad Sci U S A 98, 10869-74 (2001). 
[35] Troester, M. A. et al. Gene expression patterns associated with p53 status in breast 
cancer. BMC Cancer 6, 276 (2006). 
[36] Lim, E. et al. Aberrant luminal progenitors as the candidate target population for basal 
tumor development in BRCA1 mutation carriers. Nat Med 15, 907-13 (2009). 
[37] Chaffer, C. L. & Weinberg, R. A. Cancer cell of origin: spotlight on luminal progenitors. 
Cell Stem Cell 7, 271-2 (2010). 
[38] Nguyen, N. P. et al. Molecular biology of breast cancer stem cells: potential clinical 
applications. Cancer Treat Rev 36, 485-91 (2010). 
[39] Tanei, T. et al. Association of breast cancer stem cells identified by aldehyde 
dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-
based chemotherapy for breast cancers. Clin Cancer Res 15, 4234-41 (2009). 
[40] Charafe-Jauffret, E. et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate 
metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer 
Res 16, 45-55 (2010). 
[41] Fogel, M. et al. CD24 is a marker for human breast carcinoma. Cancer Lett 143, 87-94 
(1999). 
[42] Schindelmann, S. et al. Expression profiling of mammary carcinoma cell lines: 
correlation of in vitro invasiveness with expression of CD24. Tumour Biol 23, 139-
45 (2002). 
[43] Friedrichs, K. et al. CD44 isoforms correlate with cellular differentiation but not with 
prognosis in human breast cancer. Cancer Res 55, 5424-33 (1995). 
[44] Berner, H. S. & Nesland, J. M. Expression of CD44 isoforms in infiltrating lobular 
carcinoma of the breast. Breast Cancer Res Treat 65, 23-9 (2001). 
[45] Kufe, D. W. et al. Biological behavior of human breast carcinoma-associated antigens 
expressed during cellular proliferation. Cancer Res 43, 851-7 (1983). 
[46] Abraham, B. K. et al. Prevalence of CD44+/CD24-/low cells in breast cancer may not be 
associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 
11, 1154-9 (2005). 
[47] Duester, G. Families of retinoid dehydrogenases regulating vitamin A function: 
production of visual pigment and retinoic acid. Eur J Biochem 267, 4315-24 (2000). 
[48] Sophos, N. A. & Vasiliou, V. Aldehyde dehydrogenase gene superfamily: the 2002 
update. Chem Biol Interact 143-144, 5-22 (2003). 
[49] Ginestier, C. et al. ALDH1 is a marker of normal and malignant human mammary stem 
cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555-67 (2007). 
[50] Charafe-Jauffret, E. et al. Breast cancer cell lines contain functional cancer stem cells with 
metastatic capacity and a distinct molecular signature. Cancer Res 69, 1302-13 (2009). 
[51] Wright, M. H. et al. Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ 
cells with cancer stem cell characteristics. Breast Cancer Res 10, R10 (2008). 
www.intechopen.com
 
Breast Cancer – Focusing Tumor Microenvironment, Stem Cells and Metastasis 
 
286 
[52] Hwang-Verslues, W. W. et al. Multiple lineages of human breast cancer 
stem/progenitor cells identified by profiling with stem cell markers. PLoS One 4, 
e8377 (2009). 
[53] Goodell, M. A. et al. Dye efflux studies suggest that hematopoietic stem cells expressing 
low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 3, 
1337-45 (1997). 
[54] Scharenberg, C. W., Harkey, M. A. & Torok-Storb, B. The ABCG2 transporter is an 
efficient Hoechst 33342 efflux pump and is preferentially expressed by immature 
human hematopoietic progenitors. Blood 99, 507-12 (2002). 
[55] Dontu, G. et al. In vitro propagation and transcriptional profiling of human mammary 
stem/progenitor cells. Genes Dev 17, 1253-70 (2003). 
[56] Alvi, A. J. et al. Functional and molecular characterisation of mammary side population 
cells. Breast Cancer Res 5, R1-8 (2003). 
[57] Clarke, R. B. et al. A putative human breast stem cell population is enriched for steroid 
receptor-positive cells. Dev Biol 277, 443-56 (2005). 
[58] Liu, B. Y., McDermott, S. P., Khwaja, S. S. & Alexander, C. M. The transforming activity 
of Wnt effectors correlates with their ability to induce the accumulation of 
mammary progenitor cells. Proc Natl Acad Sci U S A 101, 4158-63 (2004). 
[59] Patrawala, L. et al. Side population is enriched in tumorigenic, stem-like cancer cells, 
whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 
65, 6207-19 (2005). 
[60] Christgen, M. et al. Identification of a distinct side population of cancer cells in the Cal-
51 human breast carcinoma cell line. Mol Cell Biochem 306, 201-12 (2007). 
[61] Hiraga, T., Ito, S. & Nakamura, H. Side population in MDA-MB-231 human breast 
cancer cells exhibits cancer stem cell-like properties without higher bone-metastatic 
potential. Oncol Rep 25, 289-96 (2011). 
[62] Zhou, S. et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of 
stem cells and is a molecular determinant of the side-population phenotype. Nat 
Med 7, 1028-34 (2001). 
[63] Zhou, S. et al. Bcrp1 gene expression is required for normal numbers of side population 
stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic 
cells in vivo. Proc Natl Acad Sci U S A 99, 12339-44 (2002). 
[64] Petrides, M., Alivisatos, B. & Frey, S. Differential activation of the human orbital, mid-
ventrolateral, and mid-dorsolateral prefrontal cortex during the processing of 
visual stimuli. Proc Natl Acad Sci U S A 99, 5649-54 (2002). 
[65] Schinkel, A. H. et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a 
deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 
491-502 (1994). 
[66] Gao, Q., Geng, L., Kvalheim, G., Gaudernack, G. & Suo, Z. Identification of cancer stem-
like side population cells in ovarian cancer cell line OVCAR-3. Ultrastruct Pathol 
33, 175-81 (2009). 
[67] Kabashima, A. et al. Side population of pancreatic cancer cells predominates in TGF-
beta-mediated epithelial to mesenchymal transition and invasion. Int J Cancer 124, 
2771-9 (2009). 
[68] Szotek, P. P. et al. Ovarian cancer side population defines cells with stem cell-like 
characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad 
Sci U S A 103, 11154-9 (2006). 
[69] Reynolds, B. A. & Weiss, S. Clonal and population analyses demonstrate that an EGF-
responsive mammalian embryonic CNS precursor is a stem cell. Dev Biol 175, 1-13 (1996). 
www.intechopen.com
 
Breast Cancer Stem Cells 
 
287 
[70] Galli, R. et al. Isolation and characterization of tumorigenic, stem-like neural precursors 
from human glioblastoma. Cancer Res 64, 7011-21 (2004). 
[71] Ponti, D. et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with 
stem/progenitor cell properties. Cancer Res 65, 5506-11 (2005). 
[72] Zhang, M. et al. Identification of tumor-initiating cells in a p53-null mouse model of 
breast cancer. Cancer Res 68, 4674-82 (2008). 
[73] Pece, S. et al. Biological and molecular heterogeneity of breast cancers correlates with 
their cancer stem cell content. Cell 140, 62-73 (2010). 
[74] Karimi-Busheri, F., Rasouli-Nia, A., Mackey, J. R. & Weinfeld, M. Senescence evasion by 
MCF-7 human breast tumor-initiating cells. Breast Cancer Res 12, R31 (2010). 
[75] Al-Hajj, M. Cancer stem cells and oncology therapeutics. Curr Opin Oncol 19, 61-4 (2007). 
[76] Clarke, M. F. et al. Cancer stem cells--perspectives on current status and future 
directions: AACR Workshop on cancer stem cells. Cancer Res 66, 9339-44 (2006). 
[77] Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties 
of stem cells. Cell 133, 704-15 (2008). 
[78] Santisteban, M. et al. Immune-induced epithelial to mesenchymal transition in vivo 
generates breast cancer stem cells. Cancer Res 69, 2887-95 (2009). 
[79] Hennessy, B. T. et al. Characterization of a naturally occurring breast cancer subset 
enriched in epithelial-to-mesenchymal transition and stem cell characteristics. 
Cancer Res 69, 4116-24 (2009). 
[80] Carthew, R. W. Gene regulation by microRNAs. Curr Opin Genet Dev 16, 203-8 (2006). 
[81] Bushati, N. & Cohen, S. M. microRNA functions. Annu Rev Cell Dev Biol 23, 175-205 
(2007). 
[82] Lu, J. et al. MicroRNA expression profiles classify human cancers. Nature 435, 834-8 (2005). 
[83] Navarro, A. & Monzo, M. MicroRNAs in human embryonic and cancer stem cells. 
Yonsei Med J 51, 622-32. 
[84] Chen, C. Z. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 353, 1768-
71 (2005). 
[85] Takamizawa, J. et al. Reduced expression of the let-7 microRNAs in human lung cancers in 
association with shortened postoperative survival. Cancer Res 64, 3753-6 (2004). 
[86] Yu, F. et al. MiR-30 reduction maintains self-renewal and inhibits apoptosis in breast 
tumor-initiating cells. Oncogene 29, 4194-204. 
[87] Cimmino, A. et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl 
Acad Sci U S A 102, 13944-9 (2005). 
[88] Bonci, D. et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting 
multiple oncogenic activities. Nat Med 14, 1271-7 (2008). 
[89] Bottoni, A. et al. miR-15a and miR-16-1 down-regulation in pituitary adenomas. J Cell 
Physiol 204, 280-5 (2005). 
[90] Bandi, N. et al. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-
dependent manner and are frequently deleted or down-regulated in non-small cell 
lung cancer. Cancer Res 69, 5553-9 (2009). 
[91] Bhattacharya, R. et al. MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. 
Cancer Res 69, 9090-5 (2009). 
[92] DeSano, J. T. & Xu, L. MicroRNA regulation of cancer stem cells and therapeutic 
implications. Aaps J 11, 682-92 (2009). 
[93] He, L. et al. A microRNA component of the p53 tumour suppressor network. Nature 
447, 1130-4 (2007). 
[94] Ji, Q. et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric 
cancer tumorspheres. BMC Cancer 8, 266 (2008). 
www.intechopen.com
 
Breast Cancer – Focusing Tumor Microenvironment, Stem Cells and Metastasis 
 
288 
[95] Ji, Q. et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. 
PLoS One 4, e6816 (2009). 
[96] Liu, C. et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis 
by directly repressing CD44. Nat Med 17, 211-5. 
[97] Godlewski, J. et al. Targeting of the Bmi-1 oncogene/stem cell renewal factor by 
microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res 68, 9125-
30 (2008). 
[98] Venkataraman, S. et al. MicroRNA 128a increases intracellular ROS level by targeting 
Bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence. 
PLoS One 5, e10748. 
[99] Kent, O. A. et al. A resource for analysis of microRNA expression and function in 
pancreatic ductal adenocarcinoma cells. Cancer Biol Ther 8, 2013-24 (2009). 
[100] Iliopoulos, D. et al. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated 
repression required for the formation and maintenance of cancer stem cells. Mol 
Cell 39, 761-72. 
[101] Hayashita, Y. et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in 
human lung cancers and enhances cell proliferation. Cancer Res 65, 9628-32 (2005). 
[102] He, L. et al. A microRNA polycistron as a potential human oncogene. Nature 435, 828-
33 (2005). 
[103] Wong, P. et al. The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell 
potential by modulating p21 expression. Cancer Res 70, 3833-42. 
[104] Connolly, E. et al. Elevated expression of the miR-17-92 polycistron and miR-21 in 
hepadnavirus-associated hepatocellular carcinoma contributes to the malignant 
phenotype. Am J Pathol 173, 856-64 (2008). 
[105] Uziel, T. et al. The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in 
medulloblastoma. Proc Natl Acad Sci U S A 106, 2812-7 (2009). 
[106] Monzo, M. et al. Overlapping expression of microRNAs in human embryonic colon 
and colorectal cancer. Cell Res 18, 823-33 (2008). 
[107] Ji, J. et al. Identification of microRNA-181 by genome-wide screening as a critical 
player in EpCAM-positive hepatic cancer stem cells. Hepatology 50, 472-80 (2009). 
[108] Wang, Y. et al. Transforming growth factor-beta regulates the sphere-initiating stem cell-
like feature in breast cancer through miRNA-181 and ATM. Oncogene 30, 1470-80. 
[109] Thiery, J. P. Epithelial-mesenchymal transitions in development and pathologies. Curr 
Opin Cell Biol 15, 740-6 (2003). 
[110] Gregory, P. A. et al. An autocrine TGF-{beta}/ZEB/miR-200 signaling network 
regulates establishment and maintenance of epithelial-mesenchymal transition. Mol 
Biol Cell. 
[111] Wellner, U. et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing 
stemness-inhibiting microRNAs. Nat Cell Biol 11, 1487-95 (2009). 
[112] Kong, D. et al. Epithelial to mesenchymal transition is mechanistically linked with 
stem cell signatures in prostate cancer cells. PLoS One 5, e12445. 
www.intechopen.com
Breast Cancer - Focusing Tumor Microenvironment, Stem cells and
Metastasis
Edited by Prof. Mehmet Gunduz
ISBN 978-953-307-766-6
Hard cover, 584 pages
Publisher InTech
Published online 14, December, 2011
Published in print edition December, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Cancer is the leading cause of death in most countries and its consequences result in huge economic, social
and psychological burden. Breast cancer is the most frequently diagnosed cancer type and the leading cause
of cancer death among females. In this book, we discussed characteristics of breast cancer cell, role of
microenvironment, stem cells and metastasis for this deadly cancer. We hope that this book will contribute to
the development of novel diagnostic as well as therapeutic approaches.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Fengyan Yu, Qiang Liu, Yujie Liu, Jieqiong Liu and Erwei Song (2011). Breast Cancer Stem Cells, Breast
Cancer - Focusing Tumor Microenvironment, Stem cells and Metastasis, Prof. Mehmet Gunduz (Ed.), ISBN:
978-953-307-766-6, InTech, Available from: http://www.intechopen.com/books/breast-cancer-focusing-tumor-
microenvironment-stem-cells-and-metastasis/breast-cancer-stem-cells-2
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
